Public
Innovation in regulation – the start of a critical conversation
Earlier this year the Minister for Innovation laid out a challenge to health regulators, the Professional Standards Authority, NICE and NHSX during an unprecedented roundtable. If the post-Brexit ambition, as outlined in the government’s Life Sciences Vision, is to provide a world-class regulatory environment that benefits patients and the public while also promoting jobs, growth, and investment, how do we collectively
HTA Business Plan 2019 - 20
This business plan sets out our priorities and objectives for the 2019/20 business year.
HTA Strategy 2019-22
Introduction from the chair
It gives me great pleasure to introduce the Human Tissue Authority’s updated strategy for 2019-22 in my capacity as the Interim Chair of the Authority. Our 2019 – 22 strategy builds on the comprehensive evaluation we conducted before developing our last 3-year strategy, and continues to focus on the three key areas of sustainability, resilience, and agility. Major themes for the next three years will continue to be a renewed focus on our people, our technology, how we collect and use information, and managing our finances.
HTA Business Plan 2020/21
This business plan sets out our priorities and objectives for the 2020/21 business year.
Business Plan and Strategy
Each Business Plan sets out our priorities and objectives for the business year, and each Strategy provides a longer term view of organisation priorities and activities, centred around our core themes of delivery, development and deployment.
Our responses to consultations
The HTA routinely responds to consultations about issues which fall inside our regulatory remit. Read our responses below